Johnson & Johnson is named one of the 12 Best Dow Jones Dividend Stocks by Hedge Funds. Scotiabank raises J&J’s target price to $265 from $230 after strong Q4 results. Despite patent pressures, J&J remains steady with 2026 sales expected to grow by 6.7% and adjusted EPS by 6.9%. The company’s portfolio is strong with 28 platforms each generating at least $1 billion a year. J&J plans to seek regulatory approvals for five drugs and file for two more this year. J&J operates globally in the healthcare sector, focusing on medical products.

Read more at Yahoo Finance: Scotiabank Raises Johnson & Johnson (JNJ) Target on Strong Quarterly Results